加速部分乳腺照射:剂量学参数与患者报告结局的相关性
本研究在2019年6月至2020年7月纳入55例接受40 Gy分10次每日一次加速部分乳腺照射(APBI)的患者,每周进行基于不良事件通用术语标准(CTCAE)的患者报告结局急性毒性评估至治疗后8周。结果显示22%患者报告中度乳房增大,27%报告最大皮肤毒性为重度或极重度,但单因素分析中所有关注的剂量学参数均与最大症状或中重度毒性无关。
要点
- 40 Gy分10次APBI期间及治疗后8周内,患者可报告中度至极重度毒性,以皮肤毒性最常见。
- 中位计划靶区体积210 cc(范围64-580 cc),中位计划靶区与同侧乳房体积比0.17(范围0.05-0.44)。
- 单因素分析中,所评估的剂量学参数均与最大症状或中重度毒性无关。
核心结论
- APBI期间及之后的每周评估显示患者经历中度至极重度毒性,以皮肤毒性最常见,但通常在放疗后8周内缓解。
- 需要在更大队列中进行更全面评估以确定与感兴趣结局对应的精确剂量学参数。
研究设计与样本
- 2019年6月至2020年7月,接受APBI的患者被分配每周一次、反应适应性的基于患者报告结局-不良事件通用术语标准(PRO-CTCAE)的急性毒性评估。
- 患者报告治疗期间及治疗后最长8周的急性毒性,并收集剂量学治疗参数。
- 采用描述性统计和单因素分析分别总结患者报告结局及其与相应剂量学指标的相关性。
- 共55例接受APBI的患者完成了351次评估。
主要发现
- 中位计划靶区体积为210 cc(范围64-580 cc),中位计划靶区与同侧乳房体积比为0.17(范围0.05-0.44)。
- 22%的患者报告中度乳房增大,27%报告最大皮肤毒性为重度或极重度。
- 35%的患者报告疲劳,44%的患者报告照射区域疼痛为中度至极重度。
- 任何中度至极重度症状首次报告的中位时间为10天(四分位距6-27天)。
- APBI后8周时,多数患者报告症状缓解,16%报告残留中度症状。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要在更大队列中进行更全面评估以确定与感兴趣结局对应的精确剂量学参数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accelerated partial breast irradiation (APBI) after breast-conserving surgery offers a well-tolerated adjuvant radiation therapy option for patients with breast cancer. We sought to describe patient-reported acute toxicity as a function of salient dosimetric parameters during and after an APBI regimen of 40 Gy in 10 once-daily fractions. METHODS AND MATERIALS: From June 2019 to July 2020, patients undergoing APBI were assigned a weekly, response-adapted, patient reported outcomes-common terminology criteria for adverse events-based acute toxicity assessment. Patients reported acute toxicity during treatment and for up to 8 weeks after treatment. Dosimetric treatment parameters were collected. Descriptive statistics and univariable analyses were used to summarize patient-reported outcomes and their correlation to corresponding dosimetric measures, respectively. RESULTS: Overall, 55 patients who received APBI completed a total of 351 assessments. Median planning target volume was 210 cc (range, 64-580 cc), and median planning target volume:ipsilateral breast volume ratio was 0.17 (range, 0.05-0.44). Overall, 22% of patients reported moderate breast enlargement and 27% reported maximum skin toxicity as severe or very severe. Furthermore, 35% of patients reported fatigue, and 44% of patients reported pain in the radiated area as moderate to very severe. Median time to first report of any moderate to very severe symptom was 10 days (interquartile range, 6-27 days). By 8 weeks after APBI, most patients reported resolution of symptoms, with 16% reporting residual moderate symptoms. Upon univariable analysis, none of the ascertained salient dosimetric parameters were associated with maximum symptoms or with the presence of moderate to very severe toxicity. CONCLUSIONS: Weekly assessments during and after APBI showed that patients experienced moderate to very severe toxicities, most commonly skin toxicity, but that these typically resolved by 8 weeks after radiation therapy. More comprehensive evaluations among larger cohorts are warranted to define the precise dosimetric parameters that correspond to outcomes of interest.
引用
- Lapen K, Fiasconaro M, Zhang Z, et al. Accelerated Partial Breast Irradiation: Association of Dosimetric Parameters With Patient-Reported Outcomes. Adv Radiat Oncol. 2023. PMID: 37305071. doi:10.1016/j.adro.2023.101263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。